Citius Oncology, Inc. Cash and Restricted Cash
Citius Oncology, Inc. (CTOR) had Cash and Restricted Cash of $16.56 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-14
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $16.56M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $2.63M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.30M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.92M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $16.56M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $2.63M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $7.30M 10-Q · filed 2026-02-13 |
| 2025-09-30 | $3.92M 10-Q · filed 2026-08-14 |
| 2025-06-30 | $112.00 10-Q · filed 2026-08-14 |
| 2025-03-31 | $112.00 10-Q · filed 2026-05-15 |
| 2024-12-31 | $112.00 10-Q · filed 2026-02-13 |
| 2024-09-30 | $112.00 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |